BC Advantage - 2017 Issue 5
Intravenous Form of Sensipar® Has Been Approved by the FDA
Subscribe or sign in to view the full article.
Article Overview
This article covers the FDA approval of an intravenous therapy for secondary hyperparathyroidism in patients with chronic kidney disease on dialysis and explains the related shift in Medicare payment status for the therapy and its oral counterpart. It is intended for readers who follow renal care, dialysis-related pharmacy, and reimbursement policy, including clinicians, pharmacists, and coding or billing professionals working with ESRD-related services. The discussion focuses on the clinical context, the Medicare bundle, and the broader operational implications for dialysis care organizations.
Why This Topic Matters
The article highlights a change that affects both treatment options and how dialysis-related medications are paid under Medicare. It is relevant to teams that need to track FDA approvals, ESRD bundled payment policy, and pharmacy integration in renal care settings.
What You Will Learn
- The clinical context for a newly approved intravenous therapy in chronic kidney disease on dialysis
- How the article connects dialysis medications to Medicare payment policy
- Why the ESRD bundled payment model matters for renal care organizations
- How pharmacy services are described within integrated dialysis care
Who Should Read This
- Nephrology clinicians
- Dialysis providers
- Pharmacists
- Medical coders and billing staff
- Healthcare reimbursement and operations professionals
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com